LIDDS AB (publ) (LIDDS.ST)

0.1565 -0.0095 (-5.72%) As of 10:15AM CEST. Market open.

LIDDS AB (publ)

Virdings allé 32B
Uppsala 754 50
Sweden

https://www.liddspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Jenni Bjornulfson	CEO, CFO & Head of IR	N/A	N/A	1971
Ms. Monica Wallter	Senior Advisor	1.87M	N/A	1956
Ms. Kia Bengtsson	Head of Clinical Development	N/A	N/A	1969
Dr. Roger Belusa	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. The company's oncology pipeline in clinical development includes Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug that binds and blocks androgen receptors; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological conditions, such as breast cancer, head and neck cancer, and prostate cancer; and Nanoimod, a NanoZolid-formulated agatolimod, which is a toll-like receptor 9 (TLR9) agonist. The company was founded in 2003 and is based in Uppsala, Sweden.

Corporate governance

LIDDS AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.